Non-Hodgkin lymphoma, pediatric

Section editor transclusions This page contains studies that were specific to pediatric populations, who are generally treated based on risk-stratification, not on the underlying histology. See individual trials for inclusion criteria.

3 regimens on this page 3 variants on this page

Untreated, pre-phase

CVP

back to top

CVP: Cyclophosphamide, Vincristine, Prednisone
COP: Cyclophosphamide, Oncovin (Vincristine), Prednisone

Regimen

Study	Years of enrollment	Evidence
Patte et al. 2007 (FAB/LMB96)	1996-2001	Non-randomized portion of phase 3 RCT

Chemotherapy

• Cyclophosphamide (Cytoxan) 300 mg/m² IV once on day 1
• Vincristine (Oncovin) 1 mg/m² IV once on day 1
• Prednisone (Sterapred) 60 mg/m²/day IV or PO on days 1 to 7

CNS prophylaxis

• Methotrexate (MTX) (dose not specified) IT once on day 1

7-day course

Subsequent treatment

• COPADM induction

References

1. FAB/LMB96: Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. link to original article link to PMC article contains verified protocol PubMed NCT00002757

Untreated, induction

COPADM

back to top

COPADM: Cyclophosphamide, Oncovin (Vincristine), Prednisone, ADriamycin (Doxorubicin), Methotrexate

Protocol

Study	Years of enrollment	Evidence
Patte et al. 2007 (FAB/LMB96)	1996-2001	Non-randomized portion of phase 3 RCT

Note: It is not clear from the manuscript whether the cyclophosphamide was fractionated.

Preceding treatment

• COP prephase

Chemotherapy

• Cyclophosphamide (Cytoxan) 250 mg/m² IV twice per day on days 2 to 4 (total dose: 1500 mg/m²)
• Vincristine (Oncovin) 2 mg/m² IV once on day 1
• Prednisone (Sterapred) 60 mg/m²/day IV or PO on days 1 to 7
• Doxorubicin (Adriamycin) 60 mg/m² IV once on day 2
• Methotrexate (MTX) 3000 mg/m² IV over 3 hours once on day 1

Supportive medications

• Folinic acid (Leucovorin)

CNS prophylaxis

• Methotrexate (MTX) (dose not specified) IT once per day on days 2 & 6

One course

Subsequent treatment

• COPADM second inducation; reduced-dose versus COPADM second inducation; standard-dose

References

1. FAB/LMB96: Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007 Apr 1;109(7):2773-80. link to original article link to PMC article contains verified protocol PubMed NCT00002757